<DOC>
	<DOCNO>NCT02728882</DOCNO>
	<brief_summary>This single-arm , multicenter Phase 2 study treat patient Recurrent refractory diffuse large B cell lymphoma infusion patient 's T cell genetically modify express chimeric antigen receptor ( CAR ) bind tumour cell express EPCAM protein cell surface.The study determine modify T cell help body 's immune system eliminate tumour cells.The trial also study safety treatment CAR-T , long CAR-T cell stay patient 's body impact treatment survival .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety With CAR-T Recurrent Refractory Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>This single-arm , multicenter Phase 2 study evaluate efficacy safety CAR-T Recurrent refractory diffuse large B cell lymphoma.The study conduct use phase I/II design . The study follow sequential phase : Part A ( screen leukapheresis , cell product preparation , cytoreductive chemotherapy ) Part B ( treatment follow-up ) . The follow-up period participant approximately 35 month final CAR-T infusion . The total duration study expect approximately 3 year . A total 24 patient may enrol period 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Confirmed pathological biopsy patient diffuse large B cell lymphoma standard solution treatment invalid recurrence refractory , flow cytometry pathological immunohistochemical examination , confirm tumor cell surface expression positive intervention molecular target , mainly CD19 ( + ) and/or CD20 ( + ) . 2 . Age 3 75 year old , male female ; 3 . Is expect survive 3 month ; 4 . Physical condition good : 02 score ECOG score ; 5 . In group four week Canon image examination evaluation body tumor load , recommend line PET CT examination . 6 . General requirement peripheral blood basic , normal blood T lymphocytes peripheral blood count must &gt; = 0.2 x10^9 / L ; 7 . No obvious abnormal heart , liver , kidney , large wound n't heal body ; 8 . Into group participate voluntarily , good adherence , cooperate test observation , childbearing age woman must 7 day start treatment expert pregnancy test result negative , sign write informed consent form . 1 . The recurrent refractory patient diffuse large B cell lymphoma . 2 . Organ failure , heart : Class III IV ; liver : Child grade liver function grade C ; kidney : kidney failure uremia stage ; lung : symptom severe respiratory failure ; brain : disorder consciousness ; 3 . Existing serious acute infection , uncontrollable , fester sex chronic infection , wound delay ; 4 . Patients significant graft versus host disease ( GVHD ) organ transplant history allogeneic hematopoietic stem cell transplantation ; 5 . Systemic autoimmune diseases immunodeficiency disease , patient allergic constitution ; 6 . Coagulation abnormality severe thrombosis ; 7 . Pregnancy lactation woman ; 8 . Any chronic disease patient treat immune agent hormone therapy ; 9 . Patients participate clinical trial clinical trial past 30 day ; 10 . The Investigator believe patient participate experiment .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma CAR-T</keyword>
</DOC>